Inhalation Sciences signs CRO contract worth 750 KSEK with global corporation based in Europe
(Stockholm 24 January, 2020) Inhalation Sciences (ISAB) has signed a CRO (Contract research) order worth 750 KSEK with a returning customer who has carried out extensive previous CRO with ISAB, and purchased ISAB lab systems.
The total value of the order is 1.1 MSEK. 750 KSEK is for services provided by ISAB, and the remaining 350 KSEK to other research companies collaborating on the project. This CRO will employ ISAB’s novel in vitro simulation tool DissolvIt, and its IPL (Isolated Perfuse Lung) module.
ISAB CEO Manoush Masarrat “When clients of this calibre return time and again, it shows that the data we deliver quite simply puts them in the lead.”
“2020 is planned to be a breakthrough year for DissolvIt, and this is a fantastic start. DissolvIt’s IVIVC (In Vitro In Vivo Correlation) capabilities are leading, generating vital data, including Cmax and Tmax curves, that until now have not been able to be captured using conventional in vitro and in vivo experiments. This year we will see that awareness of DissolvIt will increase as we see the module up and running in commercial labs generating credible, repeatable IVIVC data. This is an excellent start to 2020!”
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when being inhaled.
The information above was provided through the above contact person, by Inhalation Sciences AB, according to EU Market Abuse Regulations, for publication on January 24, 2020.